Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers
NCT ID: NCT02119754
Last Updated: 2014-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
15 participants
INTERVENTIONAL
2013-10-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers
NCT02091596
Nu-3 Gel for Infected Diabetic Foot Ulcers
NCT06020235
Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers
NCT02209662
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
NCT05608187
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
NCT06189638
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Plurogel PN
Plurogel PN
Plurogel PN
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plurogel PN
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arkios BioDevelopment International
INDUSTRY
PluroGen Therapeutics, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ledesma Foot and Ankle
Phoenix, Arizona, United States
Foot & Ankle Clinic
Los Angeles, California, United States
Samuel Merritt University
Oakland, California, United States
ASAP Urgent-Care
Hamden, Connecticut, United States
Advance Medical Research Center
Miami, Florida, United States
Miami Center for Clinical Research, LLC
Miami, Florida, United States
Unlimited Medical Research, LLC
Miami, Florida, United States
Phoenix Medical Research, LLC
Miami, Florida, United States
Med Research of Florida, LCC
Miami, Florida, United States
Sweet Hope Research Specialty, Inc.
Miami Lakes, Florida, United States
Weil Foot & Ankle Institute
Des Plaines, Illinois, United States
Research Integrity
Owensboro, Kentucky, United States
Paddington Testing Company, Inc
Philadelphia, Pennsylvania, United States
AllCare Foot & Ankle, PA
Arlington, Texas, United States
Coastal Podiatry Group
Virginia Beach, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D11AC00020
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
PGN-1300X
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.